Celsion (CLSN) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Celsion (NASDAQ:CLSN) from a hold rating to a buy rating in a research note issued to investors on Thursday.

Separately, Zacks Investment Research cut shares of Celsion from a hold rating to a sell rating in a research note on Monday, August 20th.

CLSN traded down $0.07 during trading on Thursday, hitting $2.21. 88,700 shares of the company traded hands, compared to its average volume of 251,010. The stock has a market capitalization of $36.90 million, a price-to-earnings ratio of -0.92 and a beta of 1.12. Celsion has a 1 year low of $1.75 and a 1 year high of $3.96. The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.23 and a current ratio of 4.23.

Celsion (NASDAQ:CLSN) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.19). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Celsion had a negative net margin of 4,479.42% and a negative return on equity of 109.99%. On average, equities research analysts forecast that Celsion will post -1.17 earnings per share for the current year.

An institutional investor recently raised its position in Celsion stock. BlackRock Inc. grew its holdings in Celsion Co. (NASDAQ:CLSN) by 72.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 114,844 shares of the biotechnology company’s stock after buying an additional 48,194 shares during the period. BlackRock Inc. owned approximately 0.65% of Celsion worth $339,000 as of its most recent filing with the Securities & Exchange Commission. 4.76% of the stock is owned by institutional investors.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

Featured Article: Do Tariffs Work?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply